Trial to compare two Genentech drugs

02/22/2007 | Wall Street Journal, The

Genentech is urging doctors to use its Lucentis drug to treat age-related macular degeneration, but some doctors choose to use Genentech's cancer drug Avastin instead, even though Avastin is not FDA-approved to treat eye problems. The federal government is stepping in by conducting an NIH-funded comparison trial of the two biotech drugs. BIO argues that the NIH should study cutting-edge science rather than spend money to compare two approved drugs.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations